Accelerate Diagnostics
Accelerate Diagnostics CEO Lays Out Plans at JP Morgan Healthcare Conference
The company said that it contracted 16 Pheno instruments with new US customers during Q4 and ended 2021 with 81 instruments in its US backlog.
Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.
Accelerate Diagnostics Anticipates Waning Pandemic, New Product Launches Will Boost Revenue Growth
Premium
Though the firm's financial results suffered from a lack of access to hospital lab customers in Q3, such access is already better in Q4, it said.
Accelerate Diagnostics Q3 Revenues Decline 14 Percent, Miss Analyst Revenue Estimate
During the quarter, the company brought live 11 of its current Pheno ID/AST instruments and added three contracted instruments in the US.
IVDÂ company executives noted that the acceptance and acceleration of decentralized care models have increased, enabling more effective testing for many conditions.